What the FDA labels say about taking them together
Regorafenib and rosuvastatin
Rosuvastatin's FDA label of September 4, 2026 names regorafenib in its drug interactions section; the regorafenib label PlainMeds reads does not name rosuvastatin. The rosuvastatin label: “CRESTOR dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib.”
Check it at the source: the regorafenib FDA label on DailyMed (effective February 9, 2026, Bayer HealthCare Pharmaceuticals Inc.); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the regorafenib label say about rosuvastatin?
Regorafenib's label (effective February 9, 2026) does not name rosuvastatin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Stivarga), Bayer HealthCare Pharmaceuticals Inc., effective February 9, 2026 (SPL set 824f19c9-0546-4a8a-8d8f-c4055c04f7c7), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about regorafenib?
Rosuvastatin label, drug interactionsMechanism and Clinical Effect (s): Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy and rhabdomyolysis.
Rosuvastatin label, warnings and precautionsRosuvastatin dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib [see Dosage and Administration (2.6) ].
Source: FDA drug label (Crestor, NDA021366), AstraZeneca Pharmaceuticals LP, effective April 29, 2026 (SPL set 325a5d0e-9a72-4015-9fcd-1655fb504cee), via openFDA
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Regorafenib | Rosuvastatin | |
|---|---|---|
| Labeled for | Colorectal cancer | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.0692 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once